Revenue rises 15% but product sales jump even higher, as a shift in compensation model holds back short-term revenue, the company says.
IBD's Product Sales Jump 23%, but Fee Shift Pinches Revenues
To continue, please sign in or become a member.
Join the On Wall Street
MEMBERSHIP IS FREE
- Access to essential information that independent advisors need to make informed decisions
- Exclusive E-Newsletters delivering the latest headlines to your inbox
- Access to white papers, web seminars, blogs, discussion boards, and CE exams
Have an account?
SIGN IN HERE